Glenmark Pharmaceuticals Gets Tentative Approval by USFDA for Saxagliptin Tablets

DSIJ Intelligence / 14 Jun 2017

Glenmark Pharmaceuticals Gets Tentative Approval by USFDA for Saxagliptin Tablets

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. It is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). 

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. It is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). It was granted a tentative approval by the United States Food & Drug Administration (US FDA) for Saxagliptin Tablets, 2.5 mg and 5 mg. It is the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca AB, according to a BSE filing.
 
Trading at Rs 632.95 per share, the stock was up by 0.3% at 1047 hours IST on BSE. It touched a high of Rs 635.05 and a low of Rs 628 so far during the day.
 
Glenmark Pharmaceuticals has underperformed BSE mid-cap and BSE Healthcare over a period of one year. Its peers are Alkem Laboratories and Torrent Pharmaceuticals.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.